Updates to existing prior authorization programs | |||
Drug | Plan | Eff. date | Policy & additional information |
Forteo (teriparatide), Teriparatide (teriparatide), Tymlos (abaloparatide) | Harvard Pilgrim Health Care Commercial, Tufts Health Plan Commercial, Tufts Health Direct | 11/1/2024 | Parathyroid Hormones |
Repatha, Praluent, Nexletol, Nexlizet | Harvard Pilgrim Health Care Commercial, Tufts Health Plan Commercial, Tufts Health Direct | 11/1/2024 | Lipid Lowering Agents |
Vowst (fecal microbiota spores, live-brpk) | Harvard Pilgrim Health Care Commercial, Tufts Health Plan Commercial, Tufts Health Direct | 8/13/2024 | Vowst (fecal microbiota spores, live-brpk) |
Nexletol (bempedoic acid) and Nexlizet (bempedoic acid/ezetimibe) | Tufts Health RITogether | 11/1/2024 | Nexletol (bempedoic acid) and Nexlizet (bempedoic acid/ezetimibe) |
Proton Pump Inhibitors (PPIs) | Harvard Pilgrim Health Care Commercial, Tufts Health Plan Commercial, Tufts Health Direct | 11/1/2024 | Proton Pump Inhibitors (PPIs) |
Tarpeyo | Tufts Health RITogether | 11/1/2024 | Tarpeyo |